Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Inovio pharmaceuticals, inc. save search
INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18
Published: 2021-12-14 (Crawled : 13:30) - inovio.com
INO | $10.16 -2.03% -2.67% 250K
|
Health Technology
|
| O: -1.56%
H: 0.67%
C: -1.34%
vgx-3100 treatment hpv immunotherapy therapy phase 3
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
Published: 2021-11-09 (Crawled : 13:15) - inovio.com
INO | $10.16 -2.03% -2.67% 250K
|
Health Technology
|
| O: 4.79%
H: 7.71%
C: 0.71%
covid fda vaccine phase 3 ino-4800
INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India
Published: 2021-11-03 (Crawled : 12:15) - inovio.com
INO | $10.16 -2.03% -2.67% 250K
|
Health Technology
|
| O: 2.35%
H: 0.81%
C: 0.67%
covid india vaccine phase 3 trial ino-4800
INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization
Published: 2021-10-11 (Crawled : 12:00) - prnewswire.com
INO | $10.16 -2.03% -2.67% 250K
|
Health Technology
|
| O: -1.21%
H: 5.95%
C: 3.82%
covid vaccine phase 3 authorized ino-4800
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
Published: 2021-09-22 (Crawled : 12:15) - inovio.com
INO | $10.16 -2.03% -2.67% 250K
|
Health Technology
|
| O: 0.25%
H: 0.76%
C: -1.14%
covid vaccine phase 3 trial authorized ino-4800
INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-08-26 (Crawled : 12:15) - inovio.com
INO | $10.16 -2.03% -2.67% 250K
|
Health Technology
|
| O: 4.86%
H: 8.36%
C: -1.69%
covid vaccine phase 3 trial authorized ino-4800
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-06-08 (Crawled : 12:15) - inovio.com
INO | $10.16 -2.03% -2.67% 250K
|
Health Technology
|
| O: 2.49%
H: 0.46%
C: -0.69%
covid partnership vaccine phase 3 trial ino-4800
INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800
Published: 2021-04-23 (Crawled : 12:15) - inovio.com
INO | $10.16 -2.03% -2.67% 250K
|
Health Technology
|
| O: -27.71%
H: 6.67%
C: 3.79%
phase 3 trial ino-4800
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 17M
|
TSLA | News | $162.13 12.06% 10.13% 170M
|
Consumer Durables
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.